About the Company
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
194
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CRNX News
Crinetics Pharmaceuticals gets grant for patent granted for somatostatin modulators for treating hormone-related conditions
Discover how Crinetics Pharmaceuticals Inc's patent for compounds modulating somatostatin activity can suppress hormone secretion in mammals. Explore the detailed framework for hormone modulation and ...
Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares
Marc Wilson, Chief Financial Officer of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), has sold 6,942 shares of the company on ...
Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically ...
Insiders Are Dumping These 5 Healthcare Stocks
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) is a clinical stage biopharma company that is working on treatments for endocrine ...
Crinetics gains as late-stage trial for lead drug succeeds
Crinetics Pharmaceuticals (NASDAQ:CRNX) added ~12% premarket Tuesday after its second Phase 3 trial for lead asset ...
Buy Rating Affirmed for Crinetics Pharmaceuticals Amid Impressive Paltusotine Trial Results
Crinetics Pharmaceuticals (CRNX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 19.
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001) Paltusotine was Generally Well-tolerated ...
Crinetics' hormonal disorder drug succeeds in late-stage study
Crinetics Pharmaceuticals said on Tuesday its experimental drug to treat a rare hormonal disorder met the main goal of the ...
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
Crinetics Pharmaceuticals, Inc. (CRNX) shares ended the last trading session 19.1% higher at $45.18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in ...
Crinetics Pharmaceuticals Earns ‘Buy’ Rating on Clinical Success and Market Expansion Potential
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report) on March 13 and ...
Crinetics Bags Second Phase III Win for Acromegaly, Heads for NDA Submission
The biotech Tuesday reported that 56% of patients taking paltusotine in a late-stage trial achieved the primary endpoint of ...
Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...
Chief Medical and Development Officer Dana Pizzuti of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) sold 15,089 shares of the ...
Loading the latest forecasts...